Swiss drugmaker unveils promising data for obesity drug
Extreme shortages of actinium are holding up the promising field of radiopharmaceuticals
Eisai and Biogen face uphill battle to win EU approval for Leqembi after committee’s ruling
Care Quality Commission’s shortcomings are ‘hampering’ its ability to identify poor performance, says independent review
GSK’s Shingrix is latest drug to show potential for targeting previously untreatable brain disorders
Amber alert triggered as blood stocks fall to ‘unprecedentedly low levels’
Pascal Soriot criticises decision to block breast cancer drug in England as FTSE 100 group raises profit outlook
FTSE 100 consumer group’s Mead Johnson unit hit by US litigation over baby formula death
Long waiting list for drug because of shortage of specialist services could hit patients unable to pay privately
Pharma groups could see almost threefold drop in demand due to US health official decision, says Airfinity
Proposed legislation aims to better protect data ‘supply chains’ to essential public services
Large gifts aim to boost diversity and career options amid rising costs for training doctors
Sergey Brin’s non-profit funds research into using hallucinogen for mental health treatment
The next generation of drugs vying for a slice of the potential $150bn obesity market
Shares are down 70% for the world’s largest maker of insulin pen needles and syringes since it was spun off
After a peak pandemic surge, interest in the sector has dried up
Swiss drugmaker says it will only sell medication privately if health systems cannot pay
Treatment based on science that helps axolotl salamanders restore lost limbs is now in human trials
There is concern that medications used widely for weight loss have not been tested for use by pregnant women
Federal authorities are proposing to reclassify marijuana as a less dangerous drug
Use of Car-T for lupus could drive surge in demand for a treatment that was first approved for blood cancers
Lessons from other countries highlight importance of political consensus to fix chronic funding shortfall
Pharma group seeks to catch up with rivals Eli Lilly and Novo Nordisk in sector projected to be worth $130bn a year
Health services in comparable countries have recovered faster than England, study finds
US-listed pharmacy group’s problems have been exacerbated by its struggle to move into healthcare